US Patent Application No: 2009/0022,718

Number of patents in Portfolio can not be more than 2000

Methods of treating a blood pathology using anti-TNF antibodies and fragments thereof

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
CENTOCOR, INC.MALVERN, PA73
NEW YORK UNIVERSITYNEW YORK, NY830

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Daddona, Peter Menlo Park , US 59 1267
Ghrayeb, John Downingtown , US 68 2032
Knight, David Berwyn , US 114 2158
Le, Junming Jackson Heights , US 59 1920
Siegel, Scott Westborough , US 44 1160
Vilcek, Jan New York , US 54 1632

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (7)
* 6,419,927 Method for reducing adverse effects of a human 70kDa mediator which results from endotoxin stimulation of macrophages 41 1994
* 2003/0014,891 Non-rectangular shaped credit card with case 92 2002
* 2006/0140,949 Human anti-TNF antibodies and peptides 0 2005
* 2007/0196,373 Anti-TNF antibodies and peptides of human tumor necrosis factor 80 2006
* 2007/0087,003 Methods of treating a blood pathology using anti-TNF antibodies and fragments thereof 0 2006
* 2007/0141,057 Anti-TNF antibodies and peptides of human tumor necrosis factor 0 2006
* 2008/0025,976 Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor 85 2007
 
PEPTIDE TECHNOLOGY LIMITED (1)
* 5,959,087 Tumour necrosis factor binding ligands 52 1997
 
ABBVIE DEUTSCHLAND GMBH & CO. KG (1)
* 6,914,128 Human antibodies that bind human IL-12 and methods for producing 117 2000
 
TEIJIN LIMITED (1)
* 5,075,236 Method of detecting Kawasaki disease using anti-tumor necrosis antibody 52 1988
 
SCHERING AKTIENGESELLSCHAFT (1)
* 5,506,265 Prostacyclin and carbacyclin derivatives as agents for the treatment of multiple sclerosis 12 1994
 
PHARMACIA SPA (1)
* 6,172,202 Synthesis of polymer bio-active conjugates 44 1997
 
HOECHST AKTIENGESELLSCHAFT (1)
* 5,958,413 Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor 75 1997
 
THE MATHILDA AND TERENCE KENNEDY INSTITUTE OF RHEUMATOLOGY TRUST (1)
* 5,741,488 Treatment of rheumatoid arthritis with anti-CD4 antibodies in conjunction with anti-TNF antibodies 76 1995
 
Otsuka Pharmaceutical Co., Ltd. (1)
* 5,360,716 Human tumor necrosis factor .alpha.specific monoclonal antibody and method for detecting human tumor necrosis factor .alpha. 53 1993
 
HEALTH RESEARCH, INC. (1)
* 5,342,613 Pharmaceutical compositions and use thereof in the treatment of psoriasis 42 1992
 
CDP HOLDINGS CORP. (FORMERLY GEKKO HOLDINGS CORP) (1)
* 5,223,395 Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples 54 1988
 
NEW YORK UNIVERSITY (52)
* 5,656,272 Methods of treating TNF-.alpha.-mediated Crohn's disease using chimeric anti-TNF antibodies 223 1994
* 5,919,452 Methods of treating TNF.alpha.-mediated disease using chimeric anti-TNF antibodies 99 1994
* 6,284,471 Anti-TNFa antibodies and assays employing anti-TNFa antibodies 78 1994
* 5,698,195 Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies 137 1994
* 6,277,969 Anti-TNF antibodies and peptides of human tumor necrosis factor 93 1998
* 6,790,444 Anti-TNF antibodies and peptides of human necrosis factor 34 2001
* 6,835,823 Anti-TNF antibodies and peptides of human tumor necrosis factor 38 2001
* 6,991,791 Anti-TNF antibodies and peptides of human tumor necrosis factor 40 2001
* 7,101,674 Anti-idiotypic anti-TNF antibodies and related immunoassay methods 20 2001
* 2002/0022,720 Anti-TNF antibodies and peptides of human tumor necrosis factor 5 2001
* 7,192,584 Methods of treating psoriasis with anti-TNF antibodies 76 2001
* 2002/0114,805 Methods of treating myelodysplastic syndrome with anti-TNF antibodies 0 2001
* 7,214,376 Methods of inhibiting TNF.alpha. in patients with neoplastic disease 12 2001
* 7,169,386 Methods of treating inflammation associated with viral infection with anti-TNF antibodies 13 2002
* 7,226,593 Methods of treating cachexia with chimeric anti-TNF antibodies 14 2002
* 2003/0054,004 Methods of treating cachexia with chimeric anti-TNF antibodies 0 2002
* 2002/0146,419 Methods of treating ankylosis with chimeric anti-TNF antibodies 14 2002
* 7,135,178 Methods of treating disseminated intravascular coagulation using anti-TNF antibodies 14 2002
* 7,179,466 Methods of treating rheumatoid arthritis by multiple administration of anti-TNF antibodies 14 2002
* 7,070,775 Recombinant A2-specific TNF.alpha. specific antibodies 128 2002
* 7,160,995 DNA encoding anti-TNF antibodies and peptides 13 2002
* 2003/0147,891 Anti-TNF antibodies and peptides of human tumor necrosis factor 19 2002
* 7,223,396 Methods of treatment of fistulas in Crohn's disease with anti-TNF antibodies 12 2002
* 2003/0194,402 Methods of sustained treatment of fistulas in crohn's disease with chimeric anti-TNF antibodies 0 2002
* 7,204,985 Methods of treating disseminated intravascular coagulation by multiple administration of anti-TNF antibodies 12 2003
* 7,166,284 Methods of treating joint inflammation with anti-TNF antibodies 14 2003
* 2003/0181,695 Methods of treating vascular inflammatory pathology by multiple administration of chimeric anti-TNF antibodies 0 2003
* 7,128,907 Methods of treating crohn's disease with anti-TNF antibodies 15 2003
* 2004/0115,200 Methods of treating neurodegenerative inflammation with chimeric anti-TNF antibodies 14 2003
* 7,252,823 Recombinant A2-specific TNF.alpha.-specific antibodies 11 2004
* 2004/0138,427 Anti-TNF antibodies and peptides of human tumor necrosis factor 2 2004
* 2005/0074,454 Methods of treating carcinoma using anti-TNF antibodies and peptides 8 2004
* 7,169,388 Methods of inhibiting TNF.alpha. in patients with cancer 13 2004
* 2005/0249,735 Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor 92 2004
* 2005/0260,201 Methods of treating rheumatoid arthritis using anti-TNF receptor fusion proteins 17 2005
* 2005/0255,104 Methods of treating psoriasis using anti-TNF receptor fusion proteins 13 2005
* 7,227,003 Anti-TNF antibody fragments 13 2005
* 2006/0140,946 Anti-TNF chimeric antibody fragments 0 2005
* 7,160,542 Method of treating psoriasis using human anti-TNF antibodies and fragments 13 2005
* 7,135,179 Methods for treating sarcoidosis using anti-TNF antibodies and fragments thereof 14 2005
* 2006/0018,907 Anti-TNF antibodies and peptides of human tumor necrosis factor 85 2005
* 7,404,955 Methods of inhibiting or neutralizing TNF.alpha. in patients with tissue injury 7 2005
* 2006/0024,310 Methods of treating TNFalpha-mediated tissue injury using anti-TNF antibodies and peptides 0 2005
* 7,138,118 Methods of treating rheumatoid arthritis with anti-TNF antibodies 23 2005
* 7,160,543 Methods of inhibiting TNF-.alpha. in patients with Crohn's disease 13 2005
* 7,276,239 Recombinant A2-specific TNF.alpha.-specific antibodies 101 2005
* 7,179,893 Recombinant anti-TNF-.alpha. antibodies 28 2006
* 2007/0298,040 Methods of treating seronegative arthropathy with anti-TNF antibodies 85 2006
* 7,425,330 Methods of inhibiting TNF.alpha. activity in the blood of a patient 6 2006
* 7,335,358 Methods of treating psoriasis with anti-TNF antibodies 9 2006
* 7,416,729 Methods of treating rheumatoid arthritis with anti-TNF antibodies 8 2007
* 7,374,761 Recombinant A2-specific TNF.alpha.-specific antibodies 6 2007
 
The Rockefeller University (2)
* 4,822,776 Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) 63 1985
* 6,309,640 Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) 42 1995
 
THE REGENTS OF THE UNIVERSITY OF MICHIGAN (1)
* 7,128,904 Material containing metal ion ligand complex producing nitric oxide in contact with blood 12 2002
 
L'OREAL (1)
* 5,993,833 Histamine antagonist, an interleukin-1 antagonist and/or a TNF alpha antagonist in a cosmetic, pharmaceutical or dermatological composition 50 1997
 
FARMITALIA CARLO ERBA S.R.L. (1)
* 5,436,154 Monoclonal antibodies against human Tumor Necrosis Factor .alpha. 60 1991
 
ROCKERFELLER UNIVERSITY, A CORP. OF N.Y. (1)
* 4,603,106 Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) 93 1982
 
CELLTECH R&D LIMITED (1)
* 5,994,510 Recombinant antibodies specific for TNF.alpha. 112 1995
 
BAYER HEALTHCARE LLC (1)
* 5,654,407 Human anti-TNF antibodies 148 1995
 
DANA-FARBER CANCER INSTITUTE, INC. (2)
* 5,730,975 Treatment of insulin resistance in obesity linked type II diabetes using antagonist to TNF-alpha function 47 1994
* 6,015,558 Treatment of insulin resistance in obesity linked type II diabetes using antagonists to TNF-.alpha. function 43 1998
 
ADOLOR CORPORATION (1)
* 6,190,691 Methods for treating inflammatory conditions 129 1998
 
Genentech, Inc. (1)
* 4,816,567 Recombinant immunoglobin preparations 2013 1983
 
BIOGEN, INC. (1)
* 5,750,105 Recombinant antibodies for human therapy 88 1995
 
PHARMACIA & UPJOHN S.P.A. (2)
* 5,700,788 Ureido derivatives of naphthalenephosphonic acids 38 1995
* 6,194,451 Matrix metalloproteinase inhibitors 40 1999
 
Advanced Biotherapy Concepts, Inc. (1)
* 5,888,511 Treatment of autoimmune diseases, including AIDS 146 1996
 
BRISTOL-MYERS SQUIBB PHARMA COMPANY (1)
* 5,874,441 Carbocyclic and hetertocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents 10 1997
 
BIOGEN IDEC INC. (1)
* 5,658,570 Recombinant antibodies for human therapy 163 1995
 
ABBVIE BIOTECHNOLOGY LTD (1)
* 6,090,382 Human antibodies that bind human TNF.alpha. 223 1996
 
BASF AKTIENGESELLSCHAFT (1)
* 5,231,024 Monoclonal antibodies against human tumor necrosis factor (TNF), and use thereof 183 1987
 
PHARMACIA AB (1)
* 5,776,947 Use of quinoline-3-carboxamide compounds for inhibiting the production of tumor necrosis factor (TNF) and/or for the treatment of septic shock 38 1996
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
SCIATICON AB (7)
7,708,995 Use of TNF-alpha inhibitors for treating a nerve disorder mediated by nucleus pulposus 0 2006
7,906,481 Specific TNF-A inhibitors for treating spinal disorders mediated by nucleous pulposus 0 2007
* 2008/0019,964 Use of certain drugs for treating nerve root injury 12 2007
7,811,990 Soluble cytokine receptors TNF-α blocking antibodies for treating spinal disorders mediated by nucleus pulposus 0 2007
7,723,357 Thalidomide and thalidomide derivatives for treating spinal disorders mediated by nucleus pulposus 0 2008
* 2008/0213,283 USE OF CERTAIN DRUGS FOR TREATING NERVE ROOT INJURY 8 2008
8,057,792 Use of an antibody that blocks TNF-alpha activity for treating a nerve disorder mediated by nucleus pulposus 0 2010
 
BIOASSETS DEVELOPMENT CORPORATION (3)
* 2008/0085,274 Use of certain drugs for treating nerve root injury 4 2007
* 2010/0047,235 NOVEL REGIMENS FOR TREATING DISEASES AND DISORDERS 1 2007
* 2010/0040,609 METHODS FOR PREVENTING, POSTPONING OR IMPROVING THE OUTCOME OF INVASIVE SPINAL PROCEDURES 1 2007
* Cited By Examiner